2
Introduction
PCa is the most frequently diagnosed cancer in men in the Western world. The course of PCa is largely driven by androgen receptor (AR) and, accordingly, androgen ablation therapy is a cornerstone of current therapies (1, 2) . A large proportion of patients with advanced PCa become resistant to ADT resulting in lethal castration resistant prostate cancer (CRPC). CRPC is mainly associated with genetic amplifications, mutations, or other aberration in the AR (3, 4) . Besides androgen, the role thyroid hormone thyroxine (T4) and its more active form 3,5,3'-triiodo-L-thyronine (T3) in the progression of PCa has not been comprehensively elucidated.
The thyroid hormones released into circulation are mostly bound to plasma proteins and subsequently transported to the cytosol by thyroid hormone (TH) transporters which have diverse binding affinities such as Transthyretin (TTR) and thyroxinebinding globulin (TBG) (5) . The activity of TH within the cell is regulated by (i) cell uptake involving transporters such as MCT8, (ii) metabolization by DIO1 and DIO3, two members of the iodothyronine deiodinase family and (iii) sequestration via binding to other proteins (6) such as the cytoplasmic protein CRYM, which is known to bind to T3 with high-affinity (7) . Intracellular thyroid hormone function in the prostate is dependent on CRYM expression levels (8, 9) . Previous reports demonstrated that CRYM expression was downregulated in PCa patients who underwent ADT (10) and that expression of CRYM is also downregulated in a PCa xenograft tumor model (11) . It was shown that CRYM expression is particularly low in therapy refractory PCa patient biopsies (11) . We corroborated this finding and showed that CRYM is responsive to androgens in the MDA PCa 2b cell line (10) .
The objective of this study was to define the role of thyroid hormone and its regulation by CRYM in PCa. We hypothesized that TH signaling may play an auxiliary role in PCa progression. Here we show that CRYM expression levels are lower in PCa compared to normal prostate tissue and are reduced further in 
Results

Low µ-crystallin (CRYM) expression is a negative prognostic factor and a hallmark of PCa
We assessed CRYM expression levels in malignant and adjacent normal biopsies derived from a large PCa patient cohort by immunohistochemistry (IHC). Decreased protein expression of CRYM was observed in PCa patient samples (n=178) compared to normal prostate glands (n=178), and a further reduction in CRYM expression was observed in metastatic samples (n=17, Figure 1A ). Representative IHC images of cytosolic CRYM in normal prostate, PCa and metastases are shown in Figure 1A . These findings were validated through a second independent cohort covering PCa and benign prostate tissue samples (Tuebingen Cohort, Figure 1B ).
PCa specimens (n=122) had lower CRYM protein levels as compared to benign samples (n=30). Strikingly, low mRNA expression of CRYM in metastatic PCa samples compared to primary PCa tissue was observed in multiple larger PCa patient cohorts ( Figure 1C , E, F, G, H). Furthermore, CRYM expression was significantly higher in non-neoplastic prostate glands compared to primary PCa and to samples from metastasized PCa ( Figure 1C ) (12) . Reduced CRYM expression also correlated with advanced Gleason scores or progressive 'N' stages of regional lymph node infiltration (supplementary Figure 1A , B, C). Together, these data indicate that loss of CRYM expression in PCa is an indicator for PCa aggressiveness. We analyzed the effect of CRYM expression on biochemical recurrence (BCR)-free survival by Kaplan-Meier analysis in 179 PCa Vienna cohort patients. Low CRYM expression was associated with a reduced time to BCR, indicating that low CRYM expression predicts poor prognosis ( Figure 1D ). A single patient was also assessed for CRYM and TRβ expression longitudinally within a 4-month follow-up using transurethral resections of PCa. During this period, AR and PSA expression were reduced whereas Ki-67 staining was significantly increased, suggesting progression to a highly aggressive androgen-independent neoplasia.
Indeed, we found that CRYM expression was markedly reduced and TRß level increased during progression to androgen-independency in line with our previous 5 findings (supplementary Figure 1D ). Taken together, the expression and prognostic value of CRYM reveals its role in regulation of AR and TH signaling in PCa.
CRYM enables intracellular accumulation of T3 in PCa cells
To determine the effect of CRYM on intracellular accumulation of T3, we transfected CRYM negative PCa cell lines with empty vector or CRYM expression vector ( Figure   2A ). Growth medium was supplemented with 10 nM T3 or vehicle, and after 48 hours, T3 levels were measured in the supernatants using a immunechemiluminescence assay. We observed significantly reduced levels of T3 in the medium of all CRYM re-expressing cells (PC3, 44%; DU-145, 22%; 22RV-1, 20%
and LAPC-4, 18% Figure 2A and B) compared to controls. To confirm that this reflected uptake into cells, radioactively labeled thyroid hormone [ 125 I] T3 was supplemented to the culture media. More T3 was found in PC3 and LNCaP cell lines with CRYM overexpression compared to empty vector controls ( Figure 2C ). It can be hypothesized that CRYM binds free T3 in the tumor cells, which results in increased T3 uptake and concomitantly reduced T3 levels in the growth medium.
CRYM reduces the invasive potential of PCa cells by interfering with T3
signaling WB analysis of CRYM and TRβ expression levels demonstrated that these are mutually exclusive in the androgen-independent PC-3 and DU-145 cell lines. In the androgen-dependent cell lines, both CRYM and TRβ expression could be detected ( Figure 3A ). Re-introduction of CRYM in PC-3 and DU145 cells reduced TRβ expression ( Figure 3B ). Next, we monitored the effect of high CRYM expression on invasive potential using matrigel-coated invasion chambers. CRYM overexpression significantly reduced invasion by 50% (p=0.0167) and 67% (p=0.0014) for PC3 and DU-145 cells, respectively ( Figure 3C ). This is in line with our patient data exhibiting that CRYM protein expression is downregulated in metastasizing tumors whereas TRβ expression is increased. Notably, in two independent PCa patient cohorts CRYM and THRB mRNA levels were inversely correlated in primary PCa and metastasis. Moreover, CRYM expression was significantly downregulated (cohort A: Interestingly, genes involved in AR signaling including dihydrotestosterone (DHT; n=61) and AR regulated (AR; n=46) genes were significantly downregulated ( Figure   4A ). We then compared our RNA-Seq dataset of CRYM overexpressing cells to a published RNA-Seq. dataset (17) wherein the same cell line had been treated with DHT ( Figure 4B and C). Interestingly, among the overlapping, deregulated genes, 70.1% were counter-regulated, suggesting antagonistic functions for CRYM and AR signaling. In this dataset, 843 out of 3427 significantly deregulated genes overlapped with the CRYM deregulated genes ( Figure 4C ). We performed IPA analysis on the DHT deregulated genes (>2-fold, q<0.05; n=145). As expected, progesterone, DHT, AR and metribolone regulated genes were strongly enriched and the respective pathways activated, whereas Bicalutamide and LY294002 associated genes were downregulated ( Figure 4C ). Complementary to this approach, shRNA-mediated knock-down of CRYM in LNCaP cells resulted in a significant increase in PSA levels (38±2ng/ml as compared to 10±2 ng/ml of control, Figure 4D ). Since AR protein or mRNA levels were not altered, the strong effect of CRYM overexpression on target gene expression, suggests a crosstalk between androgen and thyroid hormone signaling in PCa ( Figure 4E ).
CRYM alters the choline metabolism and metabolic shift caused by T3.
Recent studies have revealed that tumor suppressor pathways such as PTEN, p53
and RB are involved in regulation of glucose and glycine metabolism resulting in showed that intracellular choline was significantly reduced upon CRYM overexpression in PC3 cells, whereas T3 led to a slight but non-significant choline increase ( Figure 5B ). Choline is an important component for phospholipid metabolism (17) and elevated choline is a metabolic hallmark of tumor progression and a valuable diagnostic biomarker in PCa (18) Figure 5D ). PET imaging using metabolic tracers offers the opportunity not only for non-invasive diagnostics but also long-term surveillance. Interestingly, we found that overexpression of T3-buffering CRYM leads to a reduction in intracellular choline levels in PC3 cells. CHKA has a crucial role in phospholipid metabolism through catalyzing the choline phosphorylation to form phosphocholine, a phospholipid component of bilayers in cell membranes (25) . Total choline expression has been shown to be elevated in PCa tissue as compared to healthy, age matched controls (26) (27) (28) . This feature has been successfully used in combination with PET/MRI to enhance the accuracy of non-invasive diagnostics (29) . The clinical outcome of PCa is highly variable reflecting the genetic and pathophysiologic heterogeneity of the with more specific drugs with less side effects blocking the thyroid hormone pathway that could be used in the combination with AR blockers (32, 33) .
FMC-PET
In conclusion, we provide strong evidence for the protective effect of T3-buffering by CRYM in PCa. Therefore, CRYM might represent a novel biomarker for detection of good prognostic PCa. In addition, we provide a rational for how thyroid hormone metabolism could influence choline levels in PCa, which is important not only for diagnostic imaging techniques. Based on the fact that thyroid hormone signaling might act as a new oncogenic factor, our study also contributes to the understanding of aggressive PCa. Importantly new treatment avenues using novel and specific antithyroid drugs may open up and inclusion of such drugs in currently used regimens for metastatic PCa will be of interest.
Materials and methods Cell lines
PCa 
RNA and qPCR
Total RNA was isolated from cultured cells homogenised in QIAzol Lysis Reagent (Qiagen, Germany) using a single-step guanidine isothiocyanate/phenol/chloroformbased extraction technique. RNA concentration and quality were measured using a NanoDrop® 2000 UV-Vis Spectrometer (Thermo Fisher Scientific, Wilmington, USA).
Using RevertAid First Strand cDNA Synthesis Kit (ThermoFisher Scientific) 1,000 ng of RNA were reverse-transcribed to cDNA. For qPCR analysis CFX96 Real-Time PCR Detection System (BioRad, Hercules, CA, USA) was employed using Kapa Sybr Fast qPCR Master Mix (2x) Kit (Kapa Biosystems, Wilmington, MA, USA). RNA expression of target genes relative to GAPDH was quantified by 2ΔΔCT-method.
Statistical analysis was performed in GraphPad Prism 6.
Wound healing and invasion assay
Cells were grown in 24-well plates with cell culture inserts for wound healing assays.
After 48 hours, medium and inserts were removed to create a wound/gap. New medium with 10% CS-FCS (12676-011, Gibco) with or without 100 nM T3 was added and cells were incubated for a further 2 days. Migration into the empty gap was monitored using a microscope equipped with a camera. For invasion assays, matrigel-coated invasion chambers (BD Biosciences, NJ, USA) were rehydrated for 15 2 hours in RPMI 1640 medium (Gibco® Life Technologies) supplemented with 10% FCS (Gibco®). Cells (2.5x10 4 /ml) were seeded in the upper chamber in RPMI 1640/10% FCS, whereas the lower chamber contained RPMI 1680/15% FCS. After 24 hours at 37°C, medium was discarded and non-invaded cells were removed with cotton swabs from the top of the membrane, cells that migrated to the bottom of the membrane were fixed with methanol and stained with Toluidine blue. Invading cells were counted using a microscope equipped with a camera.
Gene expression profiling
Total RNA was extracted using TRIzol® Reagent (Ambion, Thermo Scientific, CA, 
Cell proliferation
LNCaP and PC3 cells were seeded into 6-well plates in triplicate at a density of 10 5 cells/ml in RPMI 1640 medium (supplemented with 10% FCS). After 24 hours cells were washed with PBS and medium was replaced with Charcoal stripped RPMI 1640 medium (Gibco). 3,3′,5-triiodo-L-thyronine (T3) were purchased from Sigma-
Aldrich and dissolved in DMSO at concentrations of 100 mM (T3). Growth medium of
LNCaP cells was supplemented with 0.1-100 ng/ml of T3 and the cells were grown for 3 days. PC3 cells were supplemented with 100ng/ml of T3 and were grown for 3 days. After trypsinization and collection by centrifugation, cells were re-suspended and counted using a hemocytometer (C-chip).
Transfection and transduction of prostate cancer cells
CRYM expressing cells were generated by transfecting PCa cells with pReceiver-M72 Empty Vector and pReceiver-M72 CRYM (for simplicity referred to in the text as CRYM(+) (GeneCopoeia) containing a green fluorescent protein (GFP) reporter gene using Lipofectamine LTX reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer`s protocol. GFP expression was evaluated under a fluorescent microscope and cells were selected using 500 μg/mL of G-418 antibiotic for 4 days (Gibco). Cells used for analysis were >70% GFP-positive. 
NMR-Based Metabolomics Analysis of Culture Media and Cell Pellets
The culture media from PC3 were filtrated using 3-kDa cutoff Nanosep centrifugal 
Multivariate Data Analysis
The SIMCA-P+ 13.0 software (Umetrics, Umeå, Sweden) was used to perform multivariate data analysis, principal component analysis (PCA) and partial leastsquares-discriminant analysis (PLS-DA) as described previously (Moazzami AA, 2011). PCA and PLS-DA models were fitted using metabolomics data from culture media or cell pellet extract of PC3 cells with and without CRYM vector and T3
treatments. In addition, separate PCA models for PC3 cells were fitted using metabolomics data from culture media or cell pellet extract with and without CRYM vector and T3 treatments. For PLS-DA models were fitted using metabolomics data from culture media and cell pellet extract, the variable importance for projection (VIP)
for each metabolite or spectral regions were implemented to determine the discriminative metabolites or spectral regions onward the first two components. 
